Effectiveness and Safety of Different Rivaroxaban Dosage Regimens in Patients with Non-Valvular Atrial Fibrillation: A Nationwide, Population-Based Cohort Study
Abstract The objective of this study is to evaluate the effectiveness of different rivaroxaban dosage regimens in preventing ischemic stroke and systemic thromboembolism among Asians. A retrospective cohort study was conducted on data from nationwide insurance claims in Taiwan. Patients with non-val...
Guardado en:
Autores principales: | , , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f39f53d69007441bb6454079715716c7 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:f39f53d69007441bb6454079715716c7 |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:f39f53d69007441bb6454079715716c72021-12-02T15:08:55ZEffectiveness and Safety of Different Rivaroxaban Dosage Regimens in Patients with Non-Valvular Atrial Fibrillation: A Nationwide, Population-Based Cohort Study10.1038/s41598-018-21884-y2045-2322https://doaj.org/article/f39f53d69007441bb6454079715716c72018-02-01T00:00:00Zhttps://doi.org/10.1038/s41598-018-21884-yhttps://doaj.org/toc/2045-2322Abstract The objective of this study is to evaluate the effectiveness of different rivaroxaban dosage regimens in preventing ischemic stroke and systemic thromboembolism among Asians. A retrospective cohort study was conducted on data from nationwide insurance claims in Taiwan. Patients with non-valvular atrial fibrillation under warfarin or rivaroxaban therapy were included. Propensity score matching was used to balance the covariates, and Cox-proportional hazard models were applied to compare the effectiveness and safety of each treatment group. Rivaroxaban was associated with a significantly lower risk of venous thromboembolism (hazard ratio [HR]: 0.51; 95% confidence interval [CI]: 0.29–0.92, P = 0.02) and intracranial hemorrhage (HR: 0.48; 95% CI: 0.32–0.72, P < 0.001) than warfarin. Rivaroxaban 20 mg and 15 mg were associated with a significantly lower risk of ischemic stroke (20 mg, HR: 0.48; CI: 0.29–0.80, P = 0.005; 15 mg, HR: 0.69; CI: 0.53–0.90, P = 0.005), but rivaroxaban 10 mg was not. In the subgroup analysis of patients older than 65 years, the results were generally the same, except that rivaroxaban had a significantly lower risk of ischemic stroke than warfarin.Hsin-Yi HuangShin-Yi LinShou-Hsia ChengChi-Chuan WangNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 8, Iss 1, Pp 1-9 (2018) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
Medicine R Science Q |
spellingShingle |
Medicine R Science Q Hsin-Yi Huang Shin-Yi Lin Shou-Hsia Cheng Chi-Chuan Wang Effectiveness and Safety of Different Rivaroxaban Dosage Regimens in Patients with Non-Valvular Atrial Fibrillation: A Nationwide, Population-Based Cohort Study |
description |
Abstract The objective of this study is to evaluate the effectiveness of different rivaroxaban dosage regimens in preventing ischemic stroke and systemic thromboembolism among Asians. A retrospective cohort study was conducted on data from nationwide insurance claims in Taiwan. Patients with non-valvular atrial fibrillation under warfarin or rivaroxaban therapy were included. Propensity score matching was used to balance the covariates, and Cox-proportional hazard models were applied to compare the effectiveness and safety of each treatment group. Rivaroxaban was associated with a significantly lower risk of venous thromboembolism (hazard ratio [HR]: 0.51; 95% confidence interval [CI]: 0.29–0.92, P = 0.02) and intracranial hemorrhage (HR: 0.48; 95% CI: 0.32–0.72, P < 0.001) than warfarin. Rivaroxaban 20 mg and 15 mg were associated with a significantly lower risk of ischemic stroke (20 mg, HR: 0.48; CI: 0.29–0.80, P = 0.005; 15 mg, HR: 0.69; CI: 0.53–0.90, P = 0.005), but rivaroxaban 10 mg was not. In the subgroup analysis of patients older than 65 years, the results were generally the same, except that rivaroxaban had a significantly lower risk of ischemic stroke than warfarin. |
format |
article |
author |
Hsin-Yi Huang Shin-Yi Lin Shou-Hsia Cheng Chi-Chuan Wang |
author_facet |
Hsin-Yi Huang Shin-Yi Lin Shou-Hsia Cheng Chi-Chuan Wang |
author_sort |
Hsin-Yi Huang |
title |
Effectiveness and Safety of Different Rivaroxaban Dosage Regimens in Patients with Non-Valvular Atrial Fibrillation: A Nationwide, Population-Based Cohort Study |
title_short |
Effectiveness and Safety of Different Rivaroxaban Dosage Regimens in Patients with Non-Valvular Atrial Fibrillation: A Nationwide, Population-Based Cohort Study |
title_full |
Effectiveness and Safety of Different Rivaroxaban Dosage Regimens in Patients with Non-Valvular Atrial Fibrillation: A Nationwide, Population-Based Cohort Study |
title_fullStr |
Effectiveness and Safety of Different Rivaroxaban Dosage Regimens in Patients with Non-Valvular Atrial Fibrillation: A Nationwide, Population-Based Cohort Study |
title_full_unstemmed |
Effectiveness and Safety of Different Rivaroxaban Dosage Regimens in Patients with Non-Valvular Atrial Fibrillation: A Nationwide, Population-Based Cohort Study |
title_sort |
effectiveness and safety of different rivaroxaban dosage regimens in patients with non-valvular atrial fibrillation: a nationwide, population-based cohort study |
publisher |
Nature Portfolio |
publishDate |
2018 |
url |
https://doaj.org/article/f39f53d69007441bb6454079715716c7 |
work_keys_str_mv |
AT hsinyihuang effectivenessandsafetyofdifferentrivaroxabandosageregimensinpatientswithnonvalvularatrialfibrillationanationwidepopulationbasedcohortstudy AT shinyilin effectivenessandsafetyofdifferentrivaroxabandosageregimensinpatientswithnonvalvularatrialfibrillationanationwidepopulationbasedcohortstudy AT shouhsiacheng effectivenessandsafetyofdifferentrivaroxabandosageregimensinpatientswithnonvalvularatrialfibrillationanationwidepopulationbasedcohortstudy AT chichuanwang effectivenessandsafetyofdifferentrivaroxabandosageregimensinpatientswithnonvalvularatrialfibrillationanationwidepopulationbasedcohortstudy |
_version_ |
1718387975199391744 |